Bionano Genomics, Inc. (BNGO): Modelo de Negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da pesquisa genômica, a Bionano Genomics (BNGO) surge como uma força transformadora, revolucionando nossa compreensão do mapeamento genético através de sua tecnologia de mapeamento de genoma óptico de ponta. Ao concluir perfeitamente a inovação científica avançada com soluções práticas de diagnóstico, a empresa desenvolveu um modelo de negócios sofisticado que capacita pesquisadores, clínicos e profissionais de biotecnologia para desbloquear idéias sem precedentes sobre estruturas genéticas e possíveis marcadores de doenças. Essa exploração abrangente do modelo de negócios da Bionao Genomics revela uma abordagem estratégica que posiciona a empresa na vanguarda da análise genômica, oferecendo detecção de variantes estruturais de alta resolução e soluções tecnológicas econômicas que estão reformulando o futuro da pesquisa genética e diagnósticos clínicos.

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: Parcerias -chave

Colaboração com instituições de pesquisa acadêmica

Em 2024, a Bionano Genomics estabeleceu parcerias com as seguintes instituições acadêmicas:

Instituição	Foco de colaboração	Ano estabelecido
Universidade de Stanford	Pesquisa genômica	2022
Escola de Medicina de Harvard	Pesquisa citogenética	2023
Universidade da Califórnia, San Diego	Mapeamento do genoma óptico	2021

Parcerias estratégicas com centros de pesquisa genômicos

A Bionano Genomics desenvolveu parcerias estratégicas com os seguintes centros de pesquisa genômicos:

• Instituto Nacional de Pesquisa do Genoma Humano (NHGRI)
• Genomics England
• Mayo Clinic Genome Center

Acordos com laboratórios de diagnóstico clínico

Parcerias laboratoriais de diagnóstico clínico a partir de 2024:

Laboratório	Tipo de parceria	Região geográfica
Diagnostics de missão	Testando a integração da plataforma	Estados Unidos
Laboratórios Arup	Implementação de mapeamento de genoma óptico	Estados Unidos
Sonic Healthcare	Colaboração de tecnologia	Global

Relacionamentos com empresas farmacêuticas e de biotecnologia

Principais parcerias da empresa farmacêutica e de biotecnologia:

• Illumina, Inc.
• Diagnóstico da Roche
• Thermo Fisher Scientific
• Novartis Pharmaceuticals

Colaborações de parceria total: 12 parcerias confirmadas nos setores de pesquisa, clínica e farmacêutica a partir de 2024.

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: Atividades -chave

Desenvolvimento da tecnologia de mapeamento de genoma óptico

A Bionano Genomics se concentra no desenvolvimento do sistema de mapeamento de genoma óptico SAPHYR® com as seguintes especificações principais:

• Capacidade de resolução: detecte variações estruturais de até 10 kilobases
• Taxa de transferência de imagem: 250 GB por execução
• Tempo de processamento da amostra: aproximadamente 3-4 horas por genoma

Pesquisa e inovação de produtos em análise genômica

Área de pesquisa	Investimento (2023)	Foco
Variação estrutural genômica	US $ 12,4 milhões	Genômica do câncer, diagnóstico de doenças raras
Desenvolvimento do algoritmo de software	US $ 7,2 milhões	Precisão de mapeamento de genoma aprimorado

Fabricação de sistemas de mapeamento genômico

Métricas de produção para sistemas Saphyr® em 2023:

• Sistemas totais fabricados: 87 unidades
• Custo médio de produção por sistema: US $ 250.000
• Locais de fabricação: San Diego, Califórnia

Desenvolvimento de software clínico e científico

Plataforma de software	Custo de desenvolvimento	Base de usuários
Bionano Solve ™ Software	US $ 5,6 milhões	Mais de 250 instituições de pesquisa
Oleoduto de análise do genoma	US $ 3,9 milhões	Laboratórios de Diagnóstico Clínico

Melhoria tecnológica contínua e validação

Métricas de aprimoramento de tecnologia para 2023:

• Despesas de P&D: US $ 24,1 milhões
• Pedidos de patente arquivados: 12
• Publicações científicas: 37 artigos revisados ​​por pares

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: Recursos -chave

Plataforma de mapeamento de genoma óptico avançado

O sistema Saphyr da Bionano Genomics representa seu principal recurso tecnológico. A partir do quarto trimestre 2023, a empresa informou:

• Base instalada total de 245 sistemas Saphyr globalmente
• Custo médio do sistema: US $ 350.000 por unidade
• Receita do contrato de manutenção: US $ 75.000 anualmente por sistema

Equipe especializada em pesquisa e engenharia genômica

Categoria de funcionários	Número	Percentagem
Total de funcionários	271	100%
Pessoal de P&D	127	46.9%
Equipe de engenharia	83	30.6%

Software de mapeamento e visualização genômicos proprietários

Os recursos de software incluem:

• Software de análise de genoma de Saphyr
• Bionano Access Cloud Platform
• Ferramentas integradas de bioinformática

Portfólio de propriedade intelectual

Categoria IP	Contagem total
Patentes emitidas	37
Aplicações de patentes pendentes	22
Total de ativos IP	59

Instalações avançadas de pesquisa e fabricação

Detalhes da instalação:

• Localização primária: San Diego, Califórnia
• Espaço total da instalação: 45.000 pés quadrados
• Capacidade de fabricação: 60 sistemas de Saphyr por trimestre

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: proposições de valor

Detecção de variantes estruturais de alta resolução

A Bionano Genomics oferece a tecnologia de mapeamento de genoma óptico (OGM) com as seguintes especificações:

Parâmetro de tecnologia	Especificação
Resolução de mapeamento do genoma	Detecção de variantes estruturais de até 250 kb
Precisão do mapeamento	99,91% de precisão
Tempo de processamento de amostra	24-48 horas

Soluções abrangentes de mapeamento de genoma

As principais soluções genômicas incluem:

• Sistema Saphyr para Mapeamento do Genoma
• Análise rara da doença constitucional
• Perfil genômico do câncer
• Pesquisa genômica agrícola

Tecnologia de análise genômica econômica

Métrica de custo	Valor
Por custo de mapeamento do genoma	Aproximadamente US $ 1.000 a US $ 1.500
Custo de sequenciamento tradicional comparativo	$3,000-$5,000

Capacidades de diagnóstico aprimoradas para distúrbios genéticos

Métricas de desempenho de diagnóstico:

• Detecção de variações estruturais complexas
• Identificação de rearranjos cromossômicos
• Precisão de triagem de transtorno genético: 97,5%

Ferramentas aprimoradas de pesquisa e tomada de decisão clínica

Aplicação de pesquisa	Capacidade
Instituições de pesquisa clínica utilizando tecnologia	Mais de 250 instituições globais
Artigos de pesquisa publicados	Mais de 500 publicações revisadas por pares

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: Relacionamentos do cliente

Suporte técnico para pesquisas e usuários clínicos

A Bionano Genomics fornece suporte técnico dedicado por meio de vários canais:

Canal de suporte	Tempo de resposta	Disponibilidade
Suporte por e -mail	24-48 horas	DIAS DA SEMANA 8:00-18:00 PST
Suporte telefônico	Imediato	Dados da semana das 9h às 17h PST
Sistema de ingressos online	72 horas no máximo	Submissão 24/7

Assistência de treinamento e implementação

Os serviços de treinamento do cliente incluem:

• Treinamento técnico no local
• Instrução baseada em webinar
• Manuais abrangentes de usuários
• Biblioteca de Tutorial em vídeo

Atualizações regulares de software e tecnologia

Atualizar frequência	Tipo de atualizações	Método de notificação
Trimestral	Patches de software	Notificações por e -mail
Bi-semestralmente	Principais versões de software	Comunicação direta do cliente

Portal de clientes on -line e centro de recursos

Recursos do portal de clientes da Bionano Genomics:

• Rastreamento de desempenho de instrumentos em tempo real
• Ferramentas de gerenciamento de dados
• Repositório de Documentação Técnica
• Fóruns de discussão da comunidade

Serviços de consulta personalizados

Tipo de consulta	Duração	Público -alvo
Consulta de estratégia de pesquisa	1-2 horas	Pesquisadores acadêmicos
Workshop de implementação clínica	Meio dia	Profissionais de laboratório clínico
Design de fluxo de trabalho personalizado	Múltiplas sessões	Grandes instituições de pesquisa

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: canais

Equipe direta de vendas direcionando instituições de pesquisa

A Bionano Genomics mantém uma equipe de vendas direta dedicada focada em instituições de pesquisa. A partir do quarto trimestre de 2023, a Companhia relatou 47 representantes de vendas diretas direcionando centros de pesquisa acadêmica, centros genômicos e laboratórios clínicos.

Tipo de canal de vendas	Segmento de destino	Número de representantes
Equipe de vendas diretas	Instituições de pesquisa	47

Produto online e plataforma de serviço

A empresa opera uma plataforma on -line abrangente para pedidos de produtos e suporte técnico. Em 2023, a plataforma digital processou aproximadamente 1.285 pedidos de produtos e solicitações de serviço.

Métricas de plataforma digital	2023 desempenho
Ordens de produto	872
Solicitações de serviço	413
Total de transações digitais	1,285

Conferências científicas e eventos da indústria

A Bionano Genomics participa ativamente de conferências científicas para mostrar suas tecnologias. Em 2023, a empresa participou de 18 principais conferências de genômica em todo o mundo.

• Reunião Anual da Sociedade Americana de Genética Humana
• Conferência Européia de Genética Humana
• Planta internacional & Conferência do Genoma Animal

Webinars e marketing digital

A empresa conduziu 24 webinars em 2023, atingindo aproximadamente 3.650 participantes profissionais em domínios de pesquisa e clínica.

Métricas de engajamento digital	2023 dados
Total de seminários on -line	24
Participantes do webinar	3,650

Parcerias com distribuidores científicos

A Bionano Genomics colabora com 12 parceiros de distribuição científica para expandir seu alcance no mercado global. Essas parcerias cobrem regiões da América do Norte, Europa e Ásia-Pacífico.

Regiões de parceiros de distribuição	Número de parceiros
América do Norte	5
Europa	4
Ásia-Pacífico	3
Total Distribution Partners	12

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: segmentos de clientes

Instituições de pesquisa acadêmica

Em 2024, a Bionano Genomics tem como alvo as instituições de pesquisa acadêmica com seu sistema de mapeamento de genoma de Saphyr. Aproximadamente 1.237 universidades de pesquisa utilizam globalmente tecnologias genômicas avançadas.

Tipo de cliente	Penetração estimada de mercado	Gastos anuais em tecnologias genômicas
Universidades de pesquisa de primeira linha	62%	US $ 3,4 milhões
Universidades de pesquisa de nível intermediário	38%	US $ 1,2 milhão

Laboratórios de Diagnóstico Clínico

Os laboratórios clínicos de diagnóstico representam um segmento crítico de clientes para a Bionano Genomics.

• Número total de laboratórios de diagnóstico clínico nos Estados Unidos: 8.700
• Taxa estimada de adoção de mercado para a tecnologia Saphyr: 17,3%
• Investimento anual médio em tecnologias de diagnóstico genômico: US $ 875.000

Organizações de pesquisa farmacêutica

As empresas farmacêuticas utilizam as tecnologias de mapeamento genômico de Bionano para desenvolvimento e pesquisa de medicamentos.

Tamanho da empresa	Número de clientes em potencial	Investimento médio de tecnologia
Grandes empresas farmacêuticas	47	US $ 5,6 milhões
Empresas farmacêuticas de tamanho médio	126	US $ 2,3 milhões

Centros de testes genéticos

Os centros de testes genéticos representam um crescente segmento de clientes para a Bionano Genomics.

• Centros de testes genéticos totais na América do Norte: 2.340
• Porcentagem usando tecnologias avançadas de mapeamento de genoma: 24,6%
• Orçamento anual da tecnologia genômica: US $ 650.000

Empresas de biotecnologia

As empresas de biotecnologia são clientes -chave para as soluções de mapeamento genômico da Bionano Genomics.

Segmento de biotecnologia	Número de clientes em potencial	Taxa de adoção de tecnologia
Biotecnologia focada na genômica	213	42.7%
Desenvolvimento terapêutico Biotecn	356	29.4%

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Bionano Genomics registrou despesas de P&D de US $ 39,7 milhões, representando um investimento significativo no desenvolvimento da tecnologia genômica.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 39,7 milhões	70.5%
2022	US $ 44,1 milhões	75.3%

Custos de fabricação e produção

A Bionano Genomics incorre em custos de fabricação relacionados principalmente ao seu sistema de mapeamento de genoma óptico SAPHYR e consumíveis.

• Custo da receita para 2023: US $ 16,4 milhões
• Margem bruta: 51,3%
• Manufatura de sobrecarga: aproximadamente US $ 5,2 milhões anualmente

Investimentos de vendas e marketing

As despesas de vendas e marketing da Bionano Genomics em 2023 totalizaram US $ 22,3 milhões.

Categoria de despesa	Quantia	Porcentagem de receita
Pessoal de vendas	US $ 12,6 milhões	35.7%
Programas de marketing	US $ 9,7 milhões	27.5%

Aquisição de pessoal e talento

As despesas operacionais totais relacionadas ao pessoal de 2023 foram de US $ 78,2 milhões.

• Total de funcionários: 283 em 31 de dezembro de 2023
• Compensação média por funcionário: US $ 276.000
• Compensação baseada em ações: US $ 15,3 milhões

Manutenção de infraestrutura de tecnologia

Custos de tecnologia e infraestrutura para manter plataformas de pesquisa genômica e sistemas computacionais.

Componente de infraestrutura	Custo anual
Sistemas de TI	US $ 3,6 milhões
Computação em nuvem	US $ 2,1 milhões
Licenças de software	US $ 1,5 milhão

Bionano Genomics, Inc. (BNGO) - Modelo de negócios: fluxos de receita

Venda de sistemas de mapeamento genômico

A partir do quarto trimestre 2023, a Bionano Genomics relatou as seguintes vendas do sistema:

Tipo de sistema	Preço médio	Unidades vendidas em 2023
Sistema Saphyr	$375,000	39 sistemas

Taxas de licenciamento de software recorrente

Bionano Genomics gerado US $ 4,1 milhões em receita de software e serviço Para o ano fiscal de 2023.

Contratos de serviço e suporte técnico

Tipo de serviço	Receita anual
Contratos de serviço anual	US $ 2,3 milhões
Acordos de suporte técnico	US $ 1,8 milhão

Acordos de pesquisa colaborativa

Em 2023, Bionano relatou US $ 3,5 milhões em colaborações de pesquisa, incluindo:

• Projetos de pesquisa financiados pelo NIH
• Acordos de parceria farmacêutica
• Colaborações de pesquisa acadêmica

Consumíveis e vendas de reagentes

Categoria de produto	Receita anual
Reagentes de mapeamento óptico	US $ 7,2 milhões
Kits consumíveis	US $ 5,6 milhões

Receita total da empresa para o ano fiscal de 2023: US $ 24,5 milhões

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Value Propositions

Superior detection of structural variants (SVs) down to 500 bp, often missed by NGS. In a comparative study for acute leukemia, Optical Genome Mapping (OGM) uniquely found 37 events, representing 15.8% of positive findings, while both OGM and targeted RNA-seq detected 175 events (74.7% of positives).

Consolidates multiple traditional cytogenetics tests into a single digital workflow. This consolidation is supported by the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association for OGM use in cytogenomic genome-wide analysis for constitutional genetic disorders. Furthermore, the final 2026 Clinical Lab Fee Schedule indicates a 47% Increase in Payment Determination for the Category I CPT code for OGM use in Hematologic Malignancies.

High-resolution, genome-wide structural variation analysis for complex diseases. The technology's utility is demonstrated by the growing body of research, with 97 new peer-reviewed publications in Q3 2025, a 10% increase year-over-year. During that same quarter, 841 human clinical research genomes were published using OGM, marking an 84% increase compared to Q3 2024.

Faster workflow from sample to SV call, in as little as three days.

Platform-agnostic software for integrated analysis of OGM, NGS, and microarray data. The VIA software, in its latest version 7.2, automates variant calling, annotation, and interpretation with Artificial Intelligence for enhanced contextualization across OGM, microarray, and next-generation sequencing (NGS) data.

The adoption and utilization metrics for the platform as of late 2025 reflect the value proposition's traction:

Metric	Q3 2025 Value	Q2 2025 Value	Year-over-Year Change (Q3 vs Q3 2024)
Installed OGM System Base	384 systems	378 systems	4% increase (Q3 2025 vs Q3 2024)
Nanochannel Array Flowcells Sold	8,390 units	7,233 units	7% increase
Consumables and Software Revenue Growth	N/A	16% increase (Q2 2025 vs Q2 2024)	15% increase (Q3 2025 vs Q3 2024)

The focus on routine users drives recurring revenue, as seen in the non-GAAP gross margin expansion:

• Non-GAAP Gross Margin in Q3 2025: 46%.
• Non-GAAP Gross Margin in Q2 2025: 52%.
• Non-GAAP Gross Margin in Q3 2024: 26%.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Customer Relationships

You're focused on driving utilization from the established user base, which is the core of the current relationship strategy for Bionano Genomics, Inc. (BNGO). This approach centers on supporting and deepening engagement with the specific customers already running Optical Genome Mapping (OGM) systems.

The company's strategy explicitly targets sustaining and supporting its base of 118 routine use customers. These core accounts are critical, as they accounted for over 80% of consumables revenue as of late 2024, a focus that continued into 2025. This emphasis on existing users is showing results in utilization metrics; for instance, flow cell purchases by these existing customers grew by 7% in the first nine months of 2025 compared to the same period a year ago. The total installed base stood at 384 OGM systems at the end of the third quarter of 2025.

Bionano Genomics, Inc. (BNGO) supports these relationships with dedicated service infrastructure. The Saphyr™ Assure Service provides an optional (opt-in) automated health monitoring feature that continuously inspects data quality and instrument performance, allowing Bionano Support to proactively repair systems with minimal downtime. This service is key for maintaining the uptime of the installed base, which saw 7 new OGM systems installed in the third quarter of 2025 alone, contributing to a year-to-date total of 23 new system installations, with expectations to surpass 25 for the full year 2025.

Scientific and educational engagement builds the community around the technology. The company supports this through direct engagement and publication metrics.

• OGM users worldwide have published on a cumulative basis nearly 11,500 clinical research genomes.
• In the third quarter of 2025, there were 97 new publications demonstrating the value of OGM, representing a 10% growth over the same period the year before.
• Over 500 publications cite OGM solutions in total.

The direct sales and support model is geared toward these high-volume, routine-use clinical and research labs. The success of this relationship focus is reflected in the Q3 2025 financial performance, where total revenue reached $7.4 million, with consumables and software revenues increasing by 15% year-over-year. The company sold 8,390 nanochannel array flowcells in that quarter.

Here's a quick look at the utilization and installed base metrics as of the end of Q3 2025:

Metric	Value	Period/Context
Routine Use Customers Supported	118	Core revenue driver focus
Flowcells Sold	8,390 units	Q3 2025
Total Installed Base	384 systems	End of Q3 2025
New Systems Installed	7 units	Q3 2025
Consumables & Software Revenue Growth	15%	Q3 2025 vs Q3 2024

The ongoing support structure, including dedicated Field Applications and Field Service teams, is essential for onboarding and sustaining these labs, ensuring they can effectively use the system for routine analysis.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Channels

You're looking at how Bionano Genomics, Inc. gets its Optical Genome Mapping (OGM) technology and data analysis tools into the hands of researchers and clinicians as of late 2025. The core strategy has definitely shifted to driving utilization from a focused group, so the channel mix reflects that intensity.

The direct sales force remains key, targeting what management calls its core group of 118 routine use customers, which, as of late 2024, accounted for over 80% of consumables revenue. This direct engagement helps push adoption in core geographies where the Americas region saw revenue increase by 9% year-over-year and EMEA sales rose by 10% in the full year 2024. That's how they are managing the near-term growth while keeping costs down.

For international reach beyond those core areas, Bionano Genomics relies on third-party distributors. The company supports its worldwide audiences through these partners, with specific mentions of activity in regions like North China (via Ecobono), Taiwan (via Pharmigene, Inc.), Thailand (via MDx Thailand), and Colombia (via Rochem Biocare S.A.S). Management also highlighted global momentum, noting research activity in regions like Japan, though specific distributor-driven revenue figures aren't broken out.

Online access is a growing channel, intrinsically linked to the installed base. The company is focused on driving utilization of its VIA software, which saw its segment grow by 11% in fiscal year 2024. In the third quarter of 2025, the combined consumables and software revenue was a strong $5.3 million out of the total reported revenue of $7.4 million for that quarter. This shows the digital component is a major revenue driver now.

Here's a quick look at how the revenue mix broke down in Q3 2025, showing the shift to recurring revenue streams:

Revenue Component	Q3 2025 Amount	Year-over-Year Growth (Q3 2025 vs Q3 2024)
Total Revenue	$7.4 million	21% increase
Consumables and Software Revenue	$5.3 million	15% increase
Nanochannel Array Flowcells Sold	8,390 units	7% increase
Instrument Revenue	$1.6 million	Change from $1.4 million in Q3 2025 vs $1.4 million in Q3 2025 (Note: Data shows $1.4M in Q2 2025 vs $2.3M in Q2 2024, and Q3 2025 instrument revenue was $1.6M vs $1.4M in Q3 2024)

Technology validation and awareness are pushed heavily through scientific channels. Bionano Genomics reported a new quarterly record of 119 peer-reviewed publications in the second quarter of 2025, followed by 97 peer-reviewed publications in the third quarter of 2025, underscoring growing scientific acceptance. They also highlighted momentum with nine studies presented at the American Society of Human Genetics (ASHG) Meeting in Q3 2025.

The diagnostic testing services channel, operating through Bionano Laboratories (Lineagen), has seen a strategic change; the company discontinued clinical services revenue, which contributed $0.7 million in Q2 2024 and $2.0 million in Q4 2023. However, the OGM-based LDTs (Laboratory Developed Tests) are supported by reimbursement pathways. Specifically, the payment determination for the Category I CPT code 81195 for hematologic malignancies, effective January 1, 2025, was set at $1263.53. This is defintely a key enabler for clinical adoption.

• OGM systems installed base reached 384 systems as of Q3 2025 end.
• The company plans to install between 25 and 30 new OGM systems in full year 2025, exceeding prior guidance.
• The company raised $10 million in a public stock offering in September 2025.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Bionano Genomics, Inc. (BNGO) serves as of late 2025, based on their Q3 2025 performance and strategic focus. The shift is clearly toward driving utilization from established users.

Academic and government research institutions focused on genomics and genetic disease.

This segment is evidenced by the scientific output Bionano Genomics supports. In the third quarter of 2025, the company saw 97 new peer-reviewed publications featuring their Optical Genome Mapping (OGM) technology. Furthermore, 841 human clinical research genomes were published using OGM during that quarter, which was an 84% increase compared to the third quarter of 2024. Research focus areas included constitutional disease, mosaicism, and oncology applications.

Clinical laboratories adopting OGM for cytogenomic analysis, especially in oncology.

Clinical adoption is being catalyzed by reimbursement milestones. For OGM use in cytogenomic genome-wide analysis for constitutional genetic disorders, the Centers for Medicare & Medicaid Services (CMS) established a preliminary payment determination of $1,263.53 effective January 1, 2025. For hematologic malignancies (blood cancers), the 2026 Clinical Lab Fee Schedule (CLFS) indicates a 47% increase for CPT code 81195, raising the payment determination from $1,263.53 to $1,853.22, effective January 1, 2026. Studies presented at the American Society of Human Genetics (ASHG) Meeting in October 2025 demonstrated OGM utility in cancer biomarker analysis and acute leukemias.

Pharmaceutical and biotechnology companies for cell line stability and gene therapy development.

While specific revenue figures for this segment aren't broken out, the technology's application in cancer research, such as the comparison of OGM to targeted RNA-sequencing in acute leukemias, shows direct relevance to drug development and validation pipelines within pharma and biotech.

Routine-use customers who account for over 80% of consumables revenue.

Bionano Genomics, Inc. is strategically focused on driving utilization from its existing base of routine users. Consumables and software revenues, which are the primary driver of utilization, accounted for $5.3 million of the total $7.4 million revenue in Q3 2025. This represented a 15% increase year-over-year for this category. The company sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase over the prior year. The total installed base supporting these routine uses reached 384 systems at the end of Q3 2025.

Early adopters in new regions like Japan leveraging OGM for complex genetics.

The CEO noted seeing strong momentum and expanding utilization in new regions, specifically mentioning Japan, where researchers are using OGM to address complex genetics questions.

Here's a quick look at the key Q3 2025 operational and financial metrics tied to these customer activities:

Metric	Value	Context
Total Revenue (Q3 2025)	$7.4 million	Total revenue for the three months ended September 30, 2025.
Consumables & Software Revenue (Q3 2025)	$5.3 million	Revenue from consumables and software in Q3 2025.
Consumables & Software Revenue Growth (YoY)	15%	Increase in consumables and software revenues in Q3 2025 versus Q3 2024.
Flowcells Sold (Q3 2025)	8,390	Nanochannel array flowcells sold in Q3 2025.
Total Installed Base (Q3 2025 End)	384 systems	Total OGM systems installed at the end of Q3 2025.
New OGM Systems Installed (Q3 2025)	7	Number of new OGM systems installed during Q3 2025.
Peer-Reviewed Publications (Q3 2025)	97	Number of peer-reviewed publications in the third quarter.
Clinical Research Genomes Published (Q3 2025)	841	Human clinical research genomes published using OGM in Q3 2025.
CPT Code 81195 Payment (Effective Jan 1, 2026)	$1,853.22	CMS 2026 CLFS payment determination for hematologic malignancy analysis.

The company's strategic emphasis is on the recurring revenue from these users, as evidenced by the 15% growth in consumables and software revenue, which is the core of their transformed business model.

You should review the full Q3 2025 filing to see if the company provided a specific percentage breakdown of revenue derived from the routine user segment versus new system sales, as the $5.3 million from consumables/software is a strong indicator of this segment's importance. Finance: draft 13-week cash view by Friday.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Cost Structure

You're looking at the cost side of Bionano Genomics, Inc. (BNGO)'s operations as of late 2025, focusing on where the cash is going to support the Optical Genome Mapping (OGM) platform. The story here is one of significant cost discipline driving margin expansion, even as they invest in the platform.

The primary cost drivers revolve around developing the OGM platform and its associated consumables. High R&D expenses for OGM platform and software development remain a foundational cost, necessary to advance the technology that underpins the entire value proposition. While specific R&D dollar amounts aren't broken out in the latest reports, the overall focus on software utilization suggests continued investment in that area.

Significant cost of goods sold (COGS) exists for manufacturing instruments and flowcells, which is directly reflected in the gross margin performance. The strategic shift toward consumables and software is clearly impacting this cost structure positively. Consumables and software revenues accounted for 72% of product revenue in Q3 2025, a mix that carries a higher margin profile than instrument sales.

The commitment to cost-saving initiatives is evident in the operating expense reduction. Non-GAAP operating expenses were reduced to $9.7 million in Q3 2025. This represents a 40% year-over-year decrease from the $16.1 million reported in Q3 2024. Honestly, that kind of reduction shows a real focus on operational efficiency.

The structure supporting the commercialization efforts-Sales, General, and Administrative (SG&A) costs for a global commercial team-is bundled within the total operating expenses. Furthermore, costs associated with intellectual property protection and regulatory compliance are ongoing, necessary expenditures for a medical technology company operating globally, though these are not itemized separately in the public summaries.

Here's a quick look at the key financial metrics reflecting this cost structure management through Q3 2025:

Metric	Q3 2025 Value	Comparison/Context
Non-GAAP Operating Expenses	$9.7 million	Represents a 40% reduction year-over-year from $16.1 million in Q3 2024.
Non-GAAP Gross Margin	46%	Material improvement from 26% in Q3 2024.
Total Revenue	$7.4 million	Up 21% compared to Q3 2024.
Flowcells Sold	8,390 units	A record, showing a 7% increase over Q3 2024.
Consumables and Software Revenue Growth	15% increase	Year-over-year growth, contributing to the higher gross margin mix.

The shift in revenue mix is a direct cost-structure lever. You can see the impact:

• Consumables and software mix was 72% of product revenue in Q3 2025.
• Instrument revenue was $1.6 million in Q3 2025.
• Instrument revenue in Q3 2024 was $1.4 million.

The company is definitely prioritizing utilization over aggressive system placement, which changes the nature of their COGS and associated costs.

Finance: draft the full 2025 projected OpEx breakdown based on the Q3 run-rate by Friday.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Revenue Streams

You're looking at how Bionano Genomics, Inc. (BNGO) brings in money, which is shifting more toward recurring revenue streams from existing users. The strategy is definitely focused on utilization now, not just putting boxes in the door.

The full-year 2025 revenue guidance remains projected to be between $26.0 million and $30.0 million. This outlook is supported by the company's focus on driving utilization within its existing installed base of Optical Genome Mapping (OGM) systems.

The revenue streams are segmented across four main areas, with a clear emphasis on the consumables and software components, which are higher margin.

For the third quarter of 2025, total revenue was $7.4 million, a 21% increase compared to the third quarter of 2024. This performance reflects the strategic shift, as prior periods included revenue from clinical services which have since been discontinued. The core business, excluding those discontinued services, saw growth.

Here's a breakdown of the revenue components based on the latest reported quarter:

Revenue Component	Q3 2025 Amount (Approximate)	Q3 2024 Amount	Year-over-Year Change (Consumables/Software)
Consumables and Software Revenue	$5.3 million	N/A	15% increase
Instrument Revenue	$1.6 million	$1.4 million	N/A
Total Revenue	$7.4 million	$6.1 million	21% increase (Total)

The consumables revenue stream is directly tied to the use of the installed base of OGM systems. You can see the volume growth in the key consumable:

• Nanochannel array flowcells sold in Q3 2025 totaled 8,390 units, which was a 7% increase from Q3 2024.
• Consumables and software together represented 72% of the product mix in Q3 2025.

Instrument revenue comes from the sale of OGM systems, such as Saphyr/Stratys. The company is actively managing the installation pace, with expectations now raised for the full year. The installed base stood at 384 systems at the end of Q3 2025, following 7 new installations during that quarter. The expectation for new OGM system installations for the full year 2025 is set to surpass 25 systems, an increase from previous guidance of 20 to 25.

Service revenue is derived from instrument maintenance contracts and OGM data services, though the company has moved away from clinical services revenue. The focus on routine users is intended to generate more predictable, recurring revenue from the consumables and software.

Software revenue from licenses and subscriptions for VIA™ and Solve™ is bundled with the consumables growth, as consumables and software sales are reported together and showed a 15% year-over-year increase in Q3 2025.

Finance: draft 13-week cash view by Friday.